Drugs / Triprilumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04413734 | Apr 2020 → Apr 2022 | intrahepatic cholangiocarcinoma | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triprilumab | “Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin” NCT04413734 ↗1“Triprilumab” NCT04413734 ↗ |
| Known as | Triprilumab Injection | “This study is to analyze the safety and efficacy of immunotherapy Triprilumab Injection combined with Gemcitabine Injection plus Cisplatin Injection in patients with advanced...” NCT04413734 ↗ |
| Route | Intravenous | “Triprilumab by intravenous infusion accompanying with Gemcitabine plus Cisplatin” NCT04413734 ↗ |